STOK

Stoke Therapeutics, Inc. (STOK) Economic Moat Analysis (2026)

Invetso Score: 2.1/10 — Weak · Last Updated: 2026-08-01

Intangible Assets

STOK does not show evidence of durable brand, patent, or regulatory-intangible protection in the provided metrics, so peers can likely replicate customer appeal and pricing over time.

Negative ROIC and ROCE indicate that any intangible advantage is not translating into excess returns, unlike stronger peers that convert IP or brand into sustained margin premium.

The absence of 5-year margin and growth evidence limits support for a persistent proprietary edge, making the moat appear weaker than peers with documented premium economics.

Switching Costs

The very low asset turnover and deeply negative ROIC suggest customers are not locked in by high switching frictions, because the business is not retaining enough value to create durable lock-in.

A negative cash conversion cycle can reflect working-capital structure, but it does not by itself prove customer dependence or contractual stickiness versus peers.

Compared with peers that benefit from embedded workflows, recurring usage, or compliance-driven retention, STOK lacks visible evidence of meaningful switching costs in the supplied data.

Network Effects

The provided metrics do not show user, transaction, or data-scale feedback loops, so there is no evidence that each additional customer makes the platform more valuable versus peers.

Negative returns on capital argue against a self-reinforcing ecosystem that is compounding into stronger economics over time.

Relative to peers with clear network-driven retention or marketplace liquidity, STOK shows no observable network effect support in the supplied information.

Cost Advantage

Negative ROIC and ROCE indicate the company is not converting its cost structure into superior unit economics, which weakens any claim to a durable cost advantage versus peers.

Asset turnover of 0.07 suggests very low asset productivity, so the business does not appear to operate with a structural efficiency edge.

Without evidence of scale purchasing power, process superiority, or lower input costs, STOK looks less advantaged than peers that can sustain margin resilience through cost leadership.

Efficient Scale

The metrics do not indicate that STOK operates in a niche where a limited market supports high returns and deters new entrants, so efficient-scale protection is not evident.

Deeply negative returns suggest the company is not capturing the economics typically associated with a protected small-market position versus peers.

Compared with peers that benefit from regulated, localized, or capacity-constrained markets, STOK shows no clear sign of structural scale-based insulation.

Overall Score

STOK shows no clear evidence of a durable economic moat in the supplied data, and its negative ROIC/ROCE plus very low asset turnover suggest weaker structural positioning than peers across all five moat drivers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Stoke Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →